August 2013 | The Journal of Targeted Therapies in Cancer

Regorafenib in the Treatment of Colorectal Cancer

September 16, 2013

Clinical Articles

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.

Overcoming Resistance to Targeted Cancer Therapy

September 11, 2013

Clinical Articles

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

Advances in Treatment and Supportive Care

August 23, 2013

Clinical Articles

Long-term safety and efficacy results from COU-AA-302 in mCRPC, and efficacy and safety data for enzalutamide monotherapy were among the ASCO 2013 Annual Meeting presentations that extended clinically useful information for the care of patients with prostate cancer.